Celldex Therapeutics, Inc. today announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation . The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with MozobilA and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells.
http://www.biospace.com/news_story.aspx?StoryID=347804&full=1
http://www.biospace.com/news_story.aspx?StoryID=347804&full=1
No comments:
Post a Comment